Litmus Health refocuses trials on quality of life and efficacy
Beta-testing has begun for Litmus Health, a data-capture platform that aims to integrate personal, home-based and wearable technology into clinical trials. Litmus brought together healthcare, bioinformatics and software development experts to create a unique platform with which to guide trial management. Dr. Samuel Volchenboum, chief science officer of Litmus Health and director of the Center for Research Informatics at the University of Chicago, said, “Litmus Health is enabling [the use of] wearables and mobile devices alongside traditional metrics to demonstrate the feasibility of the platform and to show how passive data collection can add value to traditional metrics.”
Bridge Medicines launches as a reimagining of the drug discovery path
Memorial Sloan Kettering Cancer Center (MSKCC), The Rockefeller University and Weill Cornell Medicine have formed a new drug discovery company called Bridge Medicines. The three New York City academic institutions have launched the new company in partnership with Takeda Pharmaceutical, and healthcare investment firms Bay City Capital of San Francisco and Deerfield Management of New York City, and say it will complete “a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.”
To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.
